Financial updates
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
Pharming Group N.V. presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2025.
- Full year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST® and rising demand for Joenja® (leniolisib)
- Fourth quarter 2025 total revenues increased by 15% to US$106.5 million, compared to the fourth quarter 2024
- RUCONEST® full year revenue increased by 26% to US$317.9 million and fourth quarter revenue increased by 9% to US$86.7 million
- Joenja® revenue increased by 29% to US$58.2 million and fourth quarter revenue increased by 53% to US$19.8 million
- Achieved US$25.8 million operating profit in 2025, compared to a loss in 2024
- Achieved US$54.7 million net cash flow from operations in 2025, compared to negative cash flow in the prior year
- 2026 total revenue guidance of US$405.0 – US$425.0 million (8% to 13% growth), driven by significant and accelerating growth for Joenja® and continued growth for RUCONEST®
- Advancing the clinical pipeline with key 2026 milestones including Phase II leniolisib readouts in PIDs with immune dysregulation and pivotal FALCON study enrollment completion for napazimone (KL1333) in primary mitochondrial disease
- Pharming to host a conference call today at 13:30 CET (8:30 am EDT) (view webcast)